Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

نویسندگان

  • Shinichi Umezawa
  • Akira Kubota
  • Hajime Maeda
  • Akira Kanamori
  • Kiyokazu Matoba
  • Yasuyuki Jin
  • Fuyuki Minagawa
  • Mitsuo Obana
  • Kotaro Iemitsu
  • Shogo Ito
  • Hikaru Amamiya
  • Mizuki Kaneshiro
  • Masahiko Takai
  • Hideaki Kaneshige
  • Kazuhiko Hoshino
  • Masashi Ishikawa
  • Nobuaki Minami
  • Tetsuro Takuma
  • Nobuo Sasai
  • Sachio Aoyagi
  • Takehiro Kawata
  • Atsuko Mokubo
  • Yukiko Miyairi
  • Hiroshi Takeda
  • Shin Honda
  • Hideo Machimura
  • Tetsuya Motomiya
  • Manabu Waseda
  • Yoshikazu Naka
  • Yasushi Tanaka
  • Yasuo Terauchi
  • Ikuro Matsuba
چکیده

BACKGROUND There have only been a few reports about use of dipeptidyl peptidase 4 (DPP-4) inhibitors in elderly patients with type 2 diabetes mellitus (T2DM), suggesting that the safety of these agents has not been sufficiently demonstrated. We performed a comparative review of the efficacy and safety of sitagliptin for Japanese patients with T2DM managed in the real-world clinical setting. METHODS An age-stratified analysis was performed of 831 patients who were treated with sitagliptin for 2 years. Parameters assessed included the hemoglobin A1c (HbA1c), body weight, serum creatinine, and adverse events. HbA1c and the incidence of hypoglycemia were also evaluated in patients treated with sitagliptin and a sulfonylurea (SU), who were divided into three age groups (<65 years, 65-74 years, and ≥75 years). RESULTS Comparison of glycemic control parameters, laboratory values, and adverse events revealed significant improvement of HbA1c, casual postprandial plasma glucose, and fasting plasma glucose in each age group with no change in body weight. Serum creatinine increased significantly in all age groups. Hypoglycemia only occurred in patients who received combined treatment with an SU and sitagliptin, and there was no age-related difference in its incidence. CONCLUSIONS HbA1c was improved by 2 years of sitagliptin therapy in all three age groups, and age did not seem to influence the incidence of hypoglycemic events. These results confirm the efficacy and safety of sitagliptin in patients ≥ 75 years old, suggesting that it is also useful for treating elderly patients with T2DM.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of sitagliptin on serum levels of TNF-α, IL-1β and IL-10 in patients with type 2 diabetes mellitus

Introduction: Type 2 diabetes mellitus (T2DM) is an inflammatory disease with alterations in immune system. Remarkably, cytokine imbalance plays an important role in pathogenesis of T2DM. The purpose of this study was to determine the serum levels of TNF-α, IL-1β and IL-10 and the effects of sitagliptin on the level of these cytokines in patients with T2DM. Materials and Methods: Blood samples ...

متن کامل

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)

The aim of this study was to evaluate the efficacy and safety of sitagliptin administered to elderly patients with type 2 diabetes mellitus (T2DM) for 1 year as compared with glimepiride. Patients aged ≥60 years with T2DM and inadequately controlled blood glucose were randomly assigned to sitagliptin 50 mg once daily or glimepiride 0.5 mg once daily for 52 weeks. The primary efficacy endpoint w...

متن کامل

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Meta-analysis and Systematic Review in Patients with Type 2 Diabetes Mellitus

Introduction: Diabetes mellitus has always been one of the most prevalent chronic diseases in the last decades. There exist a wide range of pharmacological agents for controlling this disease. However, these agents fare differently in terms of efficacy and safety. Hence, the aim of this study was to compare dulaglutide and liraglutide, two glucagon-like peptide-1 receptor agonists, in terms of ...

متن کامل

The Effectiveness of Acceptance and Commitment Therapy (ACT) on Psychological Symptoms and Life Satisfaction in Patients with Type-2 Diabetes

Introduction: Psychological well-being and life satisfaction in patients with chronic illnesses, including diabetes, which are often overlooked, clarify the need for more attention to appropriate treatment. The present study aims to assess the efficacy of admission and mental health treatments Cognitive and life satisfaction in patients with type 2 diabetes. Methods: The present study was a sem...

متن کامل

Efficacy and Safety of Dulaglutide Compared to Liraglutide: A Meta-analysis and Systematic Review in Patients with Type 2 Diabetes Mellitus

Introduction: Diabetes mellitus has always been one of the most prevalent chronic diseases in the last decades. There exist a wide range of pharmacological agents for controlling this disease. However, these agents fare differently in terms of efficacy and safety. Hence, the aim of this study was to compare dulaglutide and liraglutide, two glucagon-like peptide-1 receptor agonists, in terms of ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2015